ArticleEBioMedicine2019

Preclinical study using androgen receptor (AR) degradation enhancer to increase radiotherapy efficacy via targeting radiation-increased AR to better suppress prostate cancer progression.

Fu-Ju Chou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.